Molecular mechanisms behind the inhibitory effects of ginsenoside Rg3 on hepatic fibrosis: a review DOI
Zhao-feng Tian,

Rui‐yi Hu,

Zi Wang

et al.

Archives of Toxicology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 27, 2024

Language: Английский

Antifibrotic Therapies for Metabolic Dysfunction-associated Steatotic Liver Disease DOI Creative Commons
Robert F. Schwabe, Frank Tacke, Atsushi Sugimoto

et al.

JHEP Reports, Journal Year: 2025, Volume and Issue: unknown, P. 101421 - 101421

Published: April 1, 2025

Language: Английский

Citations

0
Therapeutic intervention with anti-TNF alleviates colonic and hepatic toxicity induced by perfluorooctanoic acid (PFOA) DOI

Wei Li,

Yongjing Qian,

Xiaojing Cai

et al.

Ecotoxicology and Environmental Safety, Journal Year: 2025, Volume and Issue: 296, P. 118125 - 118125

Published: April 11, 2025

Language: Английский

Citations

0
Diving deep: finding pathogenic intronic variants and making them actionable DOI
Benedikt Schaefer, Heinz Zoller

Journal of Hepatology, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

Citations

0
PNPLA3 in Alcohol‐Related Liver Disease DOI

Clélia Galvanin,

Stephan Buch, Pierre Nahon

et al.

Liver International, Journal Year: 2024, Volume and Issue: 45(1)

Published: Dec. 16, 2024

ABSTRACT The discovery of PNPLA3 as a genetic risk factor for liver disease has transformed our understanding the pathogenesis alcohol‐related (ALD). recent reclassification fatty steatotic (SLD), introducing metabolic dysfunction and (MetALD), highlighted how environmental factors synergistically drive damage. rs738409 variant stands paradigmatic example gene–environment interaction, where its effect on is dramatically amplified by alcohol consumption, obesity type 2 diabetes. Understanding these interactions revealed novel pathogenic mechanisms. robust evidence growing molecular mechanisms have made an attractive therapeutic target. Several compounds targeting are now in clinical development. While initial trials focused dysfunction‐associated SLD, recognition that almost all individuals with excessive consumption comorbidities provides unprecedented opportunity to evaluate genetically informed therapies MetALD. In this review, we examine role ALD, focusing implications context new classification framework.

Language: Английский

Citations

1
Molecular mechanisms behind the inhibitory effects of ginsenoside Rg3 on hepatic fibrosis: a review DOI
Zhao-feng Tian,

Rui‐yi Hu,

Zi Wang

et al.

Archives of Toxicology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 27, 2024

Language: Английский

Citations

1